[The role of sentinel lymph node biopsy in the management of gynecologic cancers: current evidence and institutional experience].

Authors

Kiarash Bahrehmand, Tamás Fábián, Judit Kerepesi, Zoltán Novák

Published in

Magyar onkologia. Volume 70. Issue 3. Pages 269-276. Sep 11, 2026. Epub Aug 08, 2026.

Abstract

To critically review the current role of sentinel lymph node (SLN) biopsy in endometrial, cervical, vulvar and ovarian cancer, and to compare international evidence with a single institution's surgical experience.
Targeted appraisal of randomized trials, prospective cohorts, systematic reviews and meta-analyses, complemented by retrospective, descriptive institutional data on 141 patients (indocyanine green mapping; robotic and laparoscopic platforms).
In endometrial cancer, available prospective and meta-analytic data indicate that SLN biopsy is not associated with worse oncologic outcomes than systematic lymphadenectomy. In early cervical cancer, a recent randomized trial showed that SLN biopsy alone is non-inferior to lymphadenectomy while reducing surgical morbidity. In appropriately selected vulvar cancer, groin de-escalation provides the clearest morbidity benefit. In ovarian cancer, the technique remains investigational. The institutional bilateral detection rate (78.7%) was consistent with contemporary international data.
SLN biopsy is a key surgical de-escalation strategy in gynecologic oncology which, with adequate pathological ultrastaging, also improves oncologic staging accuracy; its success depends on patient selection and centre experience.

PMID:
42731005
Bibliographic data and abstract were imported from PubMed on 13 Sep 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.